|
|
2011-6-7
Tamoxifen Citrate
CAS:54965-24-1
Products name:Tamoxifen Citrate
Structural formula:...
Tamoxifen, Citrate
|
|
|
|
|
|
|
|
|
|
|
2011-6-7
Budesonide
Molecular Formula: C25H34O6
Formula Weight: 430.53
CAS:51333-22-3
Appearance：white...
Budesonide
|
2011-6-7
Huanyangjian
CAS:71596-29-5
Product Description
Character: This product has been highly purified...
Huanyangjian
|
|
|
2011-6-7
Mifepristone
Molecular Formula: C29H35NO2
Formula Weight:...
Mifepristone
|
|
|
|
|
2011-6-7
Norgestrel
Molecular Formula: C21H28O2
Formula Weight: 312.45
CAS:6533-00-2
Appearance：white...
Norgestrel
|
|
|
2011-6-7
Norethindrone
Molecular Formula: C20H26O2
Formula Weight: 298.42
CAS:68-22-4
Appearance：white...
Norethindrone
|
2011-6-7
Metandienone
MW：300.43512
CAS：72-63-9
Standard: CP
Appearance：white fine...
Metandienone
|
2011-6-7
CAS:139755-83-2
C28H38N6O11S
Character: sildenafil citrate, sildenafil, viagra;
cure ED(Erectile...
Sildenafil
|
2011-6-7
Vardenafil
CAS:224785-91-5
Product Description
Contents: 99.90%
Property: vardenafil is white...
Vardenafil
|
2011-6-7
DHEA
Dehydroepiandrosterone
CAS:53-43-0
Appearence: White fine...
DHEA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2011-6-7
17-Methyltestosterone
MW：302.45
CAS：58-18-4
Standard: CP
Appearance：white fine...
Methyltestosterone
|
2011-6-7
Fluoxymesterone
MW： 336.44
CAS： 76-43-7
Standard: USP28
Assay:99%
Appearance：white fine...
Fluoxymesterone
|
|
|
2011-6-7
Letrozole
CAS:112809-51-5
Molecular formula :C17H11N5
Molecular weight:285.31
CAS...
Letrozole
|
2011-6-7
CAS：106650-56-0
IUPAC: N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,
N'-dimethylamine...
Sibutramine, overweight
|
2011-6-7
Nandrolone
Molecular Formula: C18H26O2
Formula Weight: 274.4
CAS:434-22-0
Appearance：white fine...
Nandrolone
|
|
|
|
|
2011-6-7
Jin Yangjian
CAS:472-61-364
Character：sex enhancer materials, sex stimulant, ED curer, improve...
Jin Yangjian
|
2011-6-7
Xinyangjian
Product Description
Character：sex enhancer materials, sex stimulant, ED curer,...
Xinyangjian
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|